By Megan Leonhardt ( October 14, 2011, 6:57 PM EDT) -- The European Commission announced Friday that it had conditionally signed off on Teva Pharmaceutical Industries Ltd.'s $6.8 billion acquisition of Cephalon Inc., after Cephalon agreed to sell its rights to market a generic version of its narcolepsy drug Provigil....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.